Companies › MavriX Bio
1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MVX-220 AAVhu68 viral vector delivering UBE3A gene | UBE3A | Phase 1 | Angelman Syndrome | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07181837 | MVX-220 | Phase 1 | Angelman Syndrome | Other | Mar 2028 |
Ionis Pharmaceuticals OHB Pediatrics Ultragenyx Pharmaceutical
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.